SEC Filing Summary: Hemispherx Biopharma, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Hemispherx Biopharma, Inc. on May 25, 2011, reporting events occurring on May 20, 2011. The filing addresses corporate governance matters, specifically the appointment of officers and compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and does not contain financial performance data.
Material Changes
The primary material change reported is the Board of Directors' approval of stock options for Wayne Springate, Senior Vice President. This action was taken pursuant to his new employment agreement and in recognition of his performance during the prior two contract periods.
Guidance, Outlook, and Management Commentary
The filing contains no guidance, outlook, or general management commentary regarding future business operations. It details a specific compensatory arrangement: Mr. Springate was granted 10-year options to purchase up to 90,000 shares of common stock at an exercise price of $0.55, which represents 110% of the closing price of the Company's Common Stock at the time. These options are issued under the Company's 2009 Equity Incentive Plan.
Key Facts for Investor Verification
- Verify the exact closing price of Hemispherx Biopharma's common stock on May 20, 2011, to confirm the $0.55 exercise price calculation.
- Review the Company's 2009 Equity Incentive Plan to confirm the availability of shares for this grant.
- Check the most recent Form 10-Q referenced in the filing for details on Wayne Springate's new employment agreement terms.
- Confirm the vesting schedule and expiration date for the 90,000 options granted.